2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Clinical Procedures, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Transplantation, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Quality of Care, Diseases, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Immunology, GVHD, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Animal Model
PAPER

2487 Phase I study with allogeneic off-the-shelf engineered Tr1 cells (TRX103) in patients undergoing HLA-mismatched related or unrelated hematopoietic stem cell transplantation (HCT) for hematological malignancies

Monzr M. M Al Malki, MD, Mark B. Juckett, MD, MHCM2, Miguel-Angel Perales, MD3, John Koreth, MD,MBBS,PhD,DPhil4, Yu Kato, PhD5, Janine Powers, PhD6, Mohamed Elgendy, MD7, Marco Londei, MD8, Maria-Grazia Roncarolo, MD9, Filippo Milano I, MD, PhD10
1 City of Hope Comprehensive Cancer Center, Duarte, California, United States
2 University of Minnesota, Minneapolis, Minnesota, United States
3 Memorial Sloan Kettering Cancer Center, New York, New York, United States
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 TR1X Bio, San Diego, California, United States
6 TR1X Bio, San Diego, California, United States
7 TR1X Bio, San Diego, California, United States
8 TR1X Bio, San Diego, California, United States
9 TR1X Bio, San Diego, California, United States
10 Fred Hutchinson Cancer Center, Seattle, Washington, United States

We conducted a first-in-human, Phase I open-label study (NCT06462365) to assess the safety and tolerability of TRX103 cell product in patients with hematological malignancies undergoing hematopoietic cell transplantation (HCT). Patients received myeloablative conditioning (MAC) or reduced-intensity conditioning (RIC) followed by peripheral blood stem cell (PBSC) transplant from an HLA-mismatched (related, or unrelated) donor. Graft-versus-host disease (GvHD) prophylaxis included post-transplant cyclophosphamide (PTCy), mycophenolate mofetil (MMF) and sirolimus.

In addition to the safety and tolerability primary endpoints, secondary and exploratory endpoints of this Phase I trial include TRX103 pharmacokinetics (PK) and pharmacodynamics (PD), GvHD prevention, overall survival and GvHD relapse free survival (GRFS) at 1-year post-HCT.

Type 1 regulatory T (Tr1) cells are a subset of interleukin-10 (IL-10) producing regulatory T cells (Tregs), with potent anti-inflammatory and immunomodulatory properties. To overcome challenges related to the use of autologous Tr1 Treg cells, Tr1X Inc. has engineered TRX103, a novel off-the-shelf T cell product that mimics the regulatory functions and cytokine secretion profile of naturally occurring Tr1 cells.

TRX103 is generated by transducing CD4+ T cells from healthy donors with a bi-directional lentiviral vector that encodes the human lL-10 gene and a non-signaling truncated form of the human nerve growth factor receptor (ΔNGFR) (M Uyeda et al., Frontiers Immunology, 2026).

Enrollment across all dose cohorts is complete, with patient follow-up and data collection ongoing. Twenty-four adults with high-risk hematological malignancies (AML, B-ALL, MDS, CMML) were enrolled, 13 were transplanted with PBSC from haploidentical donors and 11 from 1/8 or 2/10 HLA mismatched unrelated donors; 9 received MAC and 15 received RIC regimens. Twenty-three patients, evaluable for safety and PK, PD, received the TRX103 cell product across 4 different Dose Levels (DL): DL1=25 × 106, DL2=75 × 106; DL3=225 × 106; and DL4=675 × 106 TRX103 cells.

 Safety and tolerability were demonstrated in all patients. No Grade ≥ 3 AEs, serious adverse events (SAEs), or dose-limiting toxicities (DLTs) related to TRX103 infusion were observed at any DL. Three Grades 1-2 TRX103-related AEs were reported at DL3. All patients have engrafted with a median time of neutrophil engraftment of 17 days (range 14-31) and median 100% donor chimerism by day 30 (range 27-42) post-HCT.

A dose-dependent PK of TRX103 was observed, with persistence in peripheral blood for > 21 days and nonlinear exposure at DL3 and DL4. TRX103 cells expanded and maintained their ability to secrete IL-10 in vivo. Post TRX103 infusion patients showed a rapid immune reconstitution with CD4+ T cells reaching >105/ml by day 42 vs. day >100 in historical cohorts of patients receiving PTCy HCT without TRX103 (M Al Malki et al., Blood Advances, 2021; MA Perales et al., Blood Advances, 2025).  TRX103 promoted an immune reset with a rapid surge in IL-10 producing tolerogenic dendritic (DC-10) cells followed by an increase in Tr1 Tregs and FOXP3+ Tregs, compared to PTCy  HCT historical controls tested in parallel.  The tolerogenic immune reset in patients receiving TRX103 was further supported by the demonstration of operational tolerance and induction of donor-derived Tr1 cells specific for the host alloantigens.

Cumulative efficacy data are currently collected and compared to PTCy HCT historical controls, including rate of 100-day grade III-IV acute GHVD, moderate/severe chronic GvHD, nonrelapse mortality, disease-free survival, grade 2,3 infections, GRFS and overall survival.

In conclusion, TRX103 is a novel off-the shelf Tr1 Treg cell product which shows safety and preliminary immunoregulatory properties in HLA-mismatched HCT. Updated data from the Phase I first-in-human study will be presented.

Monzr M. M Al Malki, MD: incyte - Research Funding; gamida cell - Consultancy (Includes expert testimony); Ossium Health - Consultancy (Includes expert testimony); CareDx - Consultancy (Includes expert testimony); Gilead - Consultancy (Includes expert testimony); Jazz Pharma - Consultancy (Includes expert testimony); Tr1x - Consultancy (Includes expert testimony); Tscan Therapeutics - Consultancy (Includes expert testimony)